Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03968991
Other study ID # RBHP 2018 PICKERING 2
Secondary ID 2018-A03370-55
Status Terminated
Phase N/A
First received
Last updated
Start date June 18, 2019
Est. completion date December 28, 2020

Study information

Verified date January 2022
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to validate the VISIODOL® scale for screening of pain in people with visual impairment.


Description:

The VISIODOL® monocentric study conducted at Clermont-Ferrand University Hospital is a cross-disciplinary diagnostic tool validation performed in patients with acquired or congenital visual impairment and healthy sighted volunteers. Different evaluations by thermal (Pathway Médoc®) and mechanical (electronic Von Frey®) tests will allow to compare the new VISIODOL® scale with the numerical scale, which is a commonly used tool. The ergonomic quality, the satisfaction of use and the quality of life, stress, anxiety and catastrophism of the patients will also be studied.


Recruitment information / eligibility

Status Terminated
Enrollment 37
Est. completion date December 28, 2020
Est. primary completion date December 28, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Healthy volunteers - Subjects aged over 18 / under 60 - Male or female - Subjects fasting from coffee, tea, Coca-Cola and others stimulants - Sufficient understanding and cooperation to comply with the study requirements - Agreed to provide written consent - Affiliated to the social security - Subjects with visual impairment (congenital or acquired) - Subjects with no visual impairment (healthy group) Exclusion Criteria: - Subjects under 18 years old - Administrative and legal criteria (tutorship, curatorship, without social security, in exclusion period of another study)

Study Design


Intervention

Diagnostic Test:
VISIODOL® (Diagnostic tool)
Tool for assessing pain in the blind subject (with congenital or acquired deficiency)

Locations

Country Name City State
France Chu Clermont Ferrand Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using thermal tests. Determination of the correlation coefficient between NS and VISIODOL® scale for different pain temperatures by hot thermal tests. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using thermal tests. Determination of the correlation coefficient between NS and VISIODOL® scale for sensitive threshold by hot thermal tests. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using thermal tests . Determination of the correlation coefficient between NS and VISIODOL® scale for sensitive threshold by cold thermal tests. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using thermal tests. Determination of the correlation coefficient between NS and VISIODOL® scale for pain threshold by cold thermal tests. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using mechanical tests. Determination of the correlation coefficient between NS and VISIODOL® scale for sensitive threshold by electronic Von Frey®. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using mechanical tests. Determination of the correlation coefficient between NS and VISIODOL® scale for pain threshold by electronic Von Frey. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Validation of the VISIODOL® scale in screening of pain in people with visual impairment using the correlation coefficient between the intensities measured with the Numerical Scale (NS) and the VISIODOL® scale obtained by using mechanical tests. Determination of the correlation coefficient between NS and VISIODOL® scale for tolerance threshold by electronic Von Frey. The rating of the NS and VISIODOL® scales can range from 0 to 10. Day 0 + 2 hours
Secondary Comparison of pain perception between the 3 groups comparison of NS and VISIODOL® scoring for pain threshold by hot thermal tests (Pathway Medoc®). Day 0 + 1 hour
Secondary Evaluation of the ergonomic qualities of the scale ergonomic survey : Different ergonomic parameters such as length, width and granulometry will be evaluated using a questionnaire. Day 0 + 1 hour
Secondary Evaluation of satisfaction of the use of the scale satisfaction survey : The satisfaction of the participants in the study will be collected by means of a questionnaire. Day 0 + 1 hour
Secondary Evaluation of anxiety Hospital and Anxiety Depression Scale (HAD) : The Hospital Anxiety and Depression scale is a self-administered questionnaire in 14 items completed by the patient. It is used to determine the levels of anxiety and depression. Seven of the items relate to anxiety and seven relate to depression. Global score ranges from 0 to 42. Day 0 + 1 hour